Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patientsStefania Trino, Giovanni Martinelli, Giovanni Perini et al.|Oncotarget|2016Cited by 35
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemiaIlaria Iacobucci, Giovanni Martinelli, Andrea Ghelli Luserna di Rorà et al.|Journal of Hematology & Oncology|2015Cited by 28
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing PrognosisIlaria Iacobucci, Giovanni Martinelli, Anna Ferrari et al.|Blood|2013Cited by 3
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL)Ilaria Iacobucci, Giovanni Martinelli, Andrea Ghelli Luserna di Rorà et al.|Blood|2012Cited by 3
Abstract 705: Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL).Ilaria Iacobucci, Giovanni Martinelli, Andrea Ghelli Luserna di Rorà et al.|Cancer Research|2013Cited by 1